Drug Trial Radar · NCT05974267
Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)
Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
192
Actual
Start
Nov 28, 2023
Primary completion
Dec 29, 2024
Study completion Dec 29, 2024
Sponsor
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- First posted
- Aug 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the efficacy and safety of a single dose of M5717 plus pyronaridine tetraphosphate in clearing current Plasmodium falciparum infection and protecting against recurrent infections in asymptomatic adults and adolescents. The study will also assess the duration of protection provided by different doses of M5717 plus pyronaridine and the additional contribution of M5717 to the duration of protection using external study data.
Conditions
- Malaria Infection
Interventions
M5717 60 mgDrug
Participants received single oral dose (Capsules) of 60 mg M5717 on Day 1 under fasting condition
PyronaridineDrug
Participants received Pyronaridine tablets orally single dose of 720 (Participants \>= 65 kg) and 540 mg (Participants \>= 45 to \< 65 kg) on Study Day 1 under fasting condition
Atovaquone-ProguanilDrug
Participants received Atovaquone-Proguanil tablets 1000/400 mg once daily in a 3-day treatment regimen.
M5717 200 mgDrug
Participants received single oral dose (Capsules) of 200 mg M5717 on Day 1 under fasting condition
M5717 660mgDrug
Participants received single oral dose (Capsules) of 660 mg M5717 on Day 1 under fasting condition
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Parasitemia Since Negative Blood Smear After TreatmentTime frame: From treatment Day 1 up to End of observation period Day 64 (Week 10)
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Groupe de Recherche Action en Sante (GRAS)
Ouagadougou, Burkina Faso
Kisumu County Referral Hospital
Kisumu, Kenya
MRC Unit The Gambia at LSHTM
Banjul, The Gambia
Ndola Teaching Hospital
Ndola, Zambia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.